Introduction
Opioid-induced constipation (OIC) is among the most common and treatment-limiting adverse effects of opioid analgesics [1,2]. Although currently available therapies, including peripherally acting µ-opioid receptor antagonists, may alleviate symptoms, their use may be limited by gastrointestinal adverse effects [3]. In the present study, we investigated the lyophilisate of a multi-herbal preparation traditionally used for gastrointestinal dysmotility and for the regulation of gastric acid secretion [4,5]. This preparation contains extracts of Artemisia absinthium herba, Centaurium erythraea herba, Cichorium intybus planta tota, Gentiana lutea rhizoma, Juniperus communis summitates, Achillea millefolium herba, Peucedanum ostruthium rhizoma, Salvia officinalis folium, and Taraxacum planta tota. Previous work showed that this multi-herbal lyophilisate interacts with µ-opioid receptors and reverses morphine-induced inhibition of intestinal transit in mice.
Aims & Methods
We aimed to further characterise the effects of the multi-herbal lyophilisate on opioid-induced inhibition of gastrointestinal transit by assessing dose dependence and pretreatment interval, and to determine whether it affects morphine-induced analgesia. In mice, the multi-herbal lyophilisate (100, 200, 400, or 800 mg/kg, p.o.) or vehicle was administered 30 min before morphine (10 mg/kg) or vehicle. Intestinal transit was assessed using the charcoal meal test. To evaluate the influence of timing, the multi-herbal lyophilisate (400 mg/kg) or vehicle was administered 10, 20, 30, 40, 50, or 60 min before morphine or vehicle. For assessment of opioid analgesia, mice received the multi-herbal lyophilisate (400 mg/kg) or PBS by oral gavage 30 min before morphine (10 mg/kg) or WFI, and tail-flick latency was measured 30, 60, and 90 min after morphine administration.
Results
Morphine significantly reduced intestinal transit compared with vehicle (29.8% vs 49.7%, p<0.0001). The multi-herbal lyophilisate alone did not alter basal intestinal transit (46.6%). At a pretreatment interval of 30 min, 100 mg/kg was ineffective, whereas 200 and 800 mg/kg showed non-significant trends towards improvement. In contrast, 400 mg/kg significantly attenuated morphine-induced inhibition of intestinal transit (38.4%). Regarding timing, pretreatment 20 min before morphine also improved intestinal transit (37.6%), whereas no clear benefit was observed at 10, 40, 50, or 60 min. In the tail-flick assay, a slight reduction in morphine-induced analgesia was observed 30 min after morphine administration; however, this effect was not statistically significant, and no differences were detected at later timepoints. The multi-herbal lyophilisate did not affect baseline nociception.
Conclusion
This multi-herbal preparation, used for gastrointestinal dysmotility and containing nine herbal extracts, attenuated morphine-induced inhibition of intestinal transit in mice at selected doses and pretreatment intervals without impairing opioid analgesia. These findings support further evaluation of this preparation as a treatment strategy for OIC.
References
[1] Holzer P. Pharmacology of Opioids and their Effects on Gastrointestinal Function. Am J Gastroenterol Suppl 2014; 2: 9–16. doi:10.1038/ajgsup.2014.4
[2] Fruhwald S, Holzer P, Metzler H. Intestinal motility disturbances in intensive care patients pathogenesis and clinical impact. Intensiv Care Med 2007; 33: 36–44. doi:10.1007/s00134-006-0452-7
[3] Squeo F, Celiberto F, Ierardi E, et al. Opioid-induced Constipation: Old and New Concepts in Diagnosis and Treatment. J Neurogastroenterol Motil 2024; 30: 131–142. doi:10.5056/jnm23144
[4] Piqué‐Borràs M, Röhrl J, Künstle G. Herbal Amara extract induces gastric fundus relaxation via inhibition of the M2 muscarinic receptor. Neurogastroenterol Motil 2024; doi:10.1111/nmo.14924
[5] Richter P, Piqué‐Borràs M, Künstle G, et al. A Digestive Herbal Mixture Preparation Stimulates Proton Secretion in Human Parietal Cells through Phenolic Compounds Targeting Bitter Taste Receptors. Mol Nutr Food Res 2026; 70. doi:10.1002/mnfr.70443
Disclosure
All authors are employees of Weleda AG.